NEW YORK, March 13 -- Men given thrombolysis for acute ischemic stroke were three times more likely than women to have a good functional outcome, despite elevated mortality, researchers here found.
The findings came from a secondary analysis of the multicenter randomized study known as the Glycine Antagonist in Neuroprotection (GAIN) Americas trial, reported Mitchell Elkind, M.D., of Columbia University, and colleagues, in the March 13 issue of Neurology.
In that the GAIN study, published in 2001 in the Journal of the American Medical Association, 1367 ischemic stroke patients were randomized to placebo or gavestinel, an antagonist of the glycine site of the N-methyl-D-aspartate receptor. Gavestinel administered up to six hours after an acute ischemic stroke did not improve functional outcome at three months.
http://www.medpagetoday.com/Neurology/Strokes/tb1/5244
No comments:
Post a Comment